CA2269432C - Emploi du ho-1 dans les tests diagnostiques et pronostiques pour les maladies neurodegeneratives - Google Patents
Emploi du ho-1 dans les tests diagnostiques et pronostiques pour les maladies neurodegeneratives Download PDFInfo
- Publication number
- CA2269432C CA2269432C CA002269432A CA2269432A CA2269432C CA 2269432 C CA2269432 C CA 2269432C CA 002269432 A CA002269432 A CA 002269432A CA 2269432 A CA2269432 A CA 2269432A CA 2269432 C CA2269432 C CA 2269432C
- Authority
- CA
- Canada
- Prior art keywords
- concentration
- tissue
- patient
- disease
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002269432A CA2269432C (fr) | 1998-06-01 | 1999-04-19 | Emploi du ho-1 dans les tests diagnostiques et pronostiques pour les maladies neurodegeneratives |
| US09/323,248 US6210895B1 (en) | 1998-06-01 | 1999-06-01 | Ho-1 as a diagnostic and prognostic test for dementing diseases |
| US09/776,913 US20020119453A1 (en) | 1998-06-01 | 2001-02-06 | HO-1 as a diagnostic and prognostic test for dementing diseases |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2239281 CA2239281C (fr) | 1998-06-01 | 1998-06-01 | Emploi de la proteine ho-1 dans les tests diagnostiques et pronostiques des maladies neurodegeneratives |
| CA2,239,281 | 1998-06-01 | ||
| US9814198P | 1998-08-27 | 1998-08-27 | |
| US60/098,141 | 1998-08-27 | ||
| CA002269432A CA2269432C (fr) | 1998-06-01 | 1999-04-19 | Emploi du ho-1 dans les tests diagnostiques et pronostiques pour les maladies neurodegeneratives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2269432A1 CA2269432A1 (fr) | 1999-12-01 |
| CA2269432C true CA2269432C (fr) | 2002-04-02 |
Family
ID=27170716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002269432A Expired - Fee Related CA2269432C (fr) | 1998-06-01 | 1999-04-19 | Emploi du ho-1 dans les tests diagnostiques et pronostiques pour les maladies neurodegeneratives |
Country Status (2)
| Country | Link |
|---|---|
| US (2) | US6210895B1 (fr) |
| CA (1) | CA2269432C (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8440396B2 (en) * | 1997-03-14 | 2013-05-14 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| US7146209B2 (en) * | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
| US7640062B2 (en) | 2000-05-08 | 2009-12-29 | Brainsgate Ltd. | Methods and systems for management of alzheimer's disease |
| CA2483635A1 (fr) * | 2002-04-25 | 2003-11-06 | Alon Shalev | Methodes et appareil permettant de modifier les proprietes de la barriere hemato-encephalique et de la circulation cerebrale a l'aide d'effets neuroexcitateurs et/ou neuroinhibiteurs d'agents odorants sur les nerfs de la tete |
| US7684859B2 (en) * | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
| JP2006515999A (ja) * | 2002-11-14 | 2006-06-15 | ブレインズゲート リミティド | 刺激のための外科用ツール及び技法 |
| US20060094064A1 (en) * | 2003-11-19 | 2006-05-04 | Sandip Ray | Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids |
| EP2211183B1 (fr) | 2003-11-19 | 2013-03-06 | Satoris, Inc. | Procédé de diagnostic et surveillance de la maladie d'Alzheimer |
| US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
| US8010189B2 (en) * | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
| US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
| WO2006021957A2 (fr) * | 2004-08-23 | 2006-03-02 | Brainsgate Ltd. | Modulation bilaterale concurrente de ganglions spheno-palatins |
| US7851172B2 (en) | 2006-07-25 | 2010-12-14 | University Of Kentucky Research Foundation | Biomarkers of mild cognitive impairment and alzheimer's disease |
| US20090210026A1 (en) * | 2006-08-17 | 2009-08-20 | Brainsgate Ltd. | Spg stimulation for enhancing neurogenesis and brain metabolism |
| US20090018094A1 (en) * | 2006-12-01 | 2009-01-15 | Loma Linda University Medical Center | Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration |
| US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
| US20100124756A1 (en) * | 2008-10-10 | 2010-05-20 | Sandip Ray | Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids |
| US20110237537A1 (en) * | 2009-05-29 | 2011-09-29 | Lombard Jay L | Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis |
| US8355927B2 (en) | 2010-11-05 | 2013-01-15 | Genomind, Llc | Neuropsychiatric test reports |
| EP2459742B1 (fr) | 2009-07-29 | 2016-04-06 | Pharnext | Nouveaux outils diagnostiques pour la maladie d'alzheimer |
| US20110202284A1 (en) * | 2010-02-10 | 2011-08-18 | Mcreynolds Cristopher | Novel groups of biomarkers for diagnosing alzheimer's disease |
| RU2455646C1 (ru) * | 2011-04-27 | 2012-07-10 | Учреждение Российской Академии Медицинских Наук Научно-Исследовательский Институт Психического Здоровья Сибирского Отделения Российской Академии Медицинских Наук | Способ прогнозирования течения пограничных психических расстройств |
| EP3255435A1 (fr) | 2012-04-13 | 2017-12-13 | Oasis Diagnostics Corporation | Biomarqueurs salivaires spécifiques pour la détection de risques, le diagnostic précoce, le pronostic et la surveillance de la maladie d'alzheimer et de la maladie de parkinson |
| US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
| EP3093043B1 (fr) | 2015-05-13 | 2018-11-14 | Brainsgate Ltd. | Implant et système de distribution pour stimulateur neural |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996040896A1 (fr) | 1995-06-07 | 1996-12-19 | Athena Neurosciences, Inc. | Procede pour identifier une therapeutique de la maladie d'alzheimer a l'aide de modeles animaux transgeniques |
-
1999
- 1999-04-19 CA CA002269432A patent/CA2269432C/fr not_active Expired - Fee Related
- 1999-06-01 US US09/323,248 patent/US6210895B1/en not_active Expired - Fee Related
-
2001
- 2001-02-06 US US09/776,913 patent/US20020119453A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20020119453A1 (en) | 2002-08-29 |
| CA2269432A1 (fr) | 1999-12-01 |
| US6210895B1 (en) | 2001-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2269432C (fr) | Emploi du ho-1 dans les tests diagnostiques et pronostiques pour les maladies neurodegeneratives | |
| US7897361B2 (en) | Methods of diagnosing Alzheimer's disease | |
| Ikonomovic et al. | Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology | |
| KR20080034874A (ko) | 알츠하이머병을 진단하는 방법 | |
| JP2011529344A (ja) | アルツハイマー病の刺激誘発ゲノムプロフィールマーカー | |
| US7105485B2 (en) | HO-1 suppressor as a diagnostic and prognostic test for dementing diseases | |
| Conti et al. | Pigment epithelium‐derived factor is differentially expressed in peripheral neuropathies | |
| Harrison et al. | Regional and neuronal reductions of polyadenylated messenger RNA in Alzheimer's disease | |
| US7049078B2 (en) | Apolipoprotein E polymorphism and treatment of alzheimer's disease | |
| WO2003104466A1 (fr) | Traitement du dysfonctionnement vasculaire et maladie d'alzheimer | |
| Conti et al. | Differential expression of ceruloplasmin isoforms in the cerebrospinal fluid of amyotrophic lateral sclerosis patients | |
| CA2574224A1 (fr) | Technique diagnostique moleculaire et traitement de la demence a corps de lewy | |
| JP2002531063A (ja) | アルツハイマー症の診断又は予後の方法 | |
| EP1188839A1 (fr) | Utilisations d'une protéine membranaire associée intrinsèquement avec une cavéole pour le diagnostic et la thérapie de la maladie d'alzheimer et de maladies neurodégénératives apparentées | |
| US6962776B2 (en) | Methods and materials for evaluating cardiovascular conditions | |
| CA2239281C (fr) | Emploi de la proteine ho-1 dans les tests diagnostiques et pronostiques des maladies neurodegeneratives | |
| Praticò | Oxidative imbalance and lipid peroxidation in Alzheimer's disease | |
| WO2024075803A1 (fr) | Méthode de test, de traitement ou de prévention d'une maladie du nerf crânien | |
| EP1189060A1 (fr) | Procédé de diagnostic pour la maladie d'Alzheimer utilisant la protéine phosphorylée PEA-15 | |
| KR20240118211A (ko) | Timp-3를 이용한 경도인지장애 또는 알츠하이머성 치매의 진단 방법 | |
| AU2011253636B2 (en) | Methods and compositions relating to alzheimer's disease | |
| WO2023220276A1 (fr) | PROCÉDÉS DE DÉTECTION DE PROTÉOFORMES Aβ ET LEUR UTILISATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |